News & Videos - INOVIO PHARMACEUTICALS INC.

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants PR Newswire PLYMOUTH MEETING, Pa., April 15, 2024 PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. ( Nasdaq : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of...

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine PR Newswire PLYMOUTH MEETING, Pa., March 26, 2024 PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will participate in The Novel Therapeutics Forum hosted...

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire PLYMOUTH MEETING, Pa., March 6, 2024 Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy Designation granted by U.S. Food and Drug Administration (FDA) Received FDA feedback that data from completed...

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 PR Newswire PLYMOUTH MEETING, Pa., Feb. 21, 2024 PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on...

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire PLYMOUTH MEETING, Pa., Feb. 7, 2024 PLYMOUTH MEETING, Pa. , Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will present at the Oppenheimer 34th Annual Healthcare Life...

INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Feb. 2, 2024 PLYMOUTH MEETING, Pa. , Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation...

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split PR Newswire PLYMOUTH MEETING, Pa., Jan. 23, 2024 PLYMOUTH MEETING, Pa. , Jan. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time...

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader PR Newswire PLYMOUTH MEETING, Pa., Jan. 22, 2024 Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET PLYMOUTH MEETING, Pa. , Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people...

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) PR Newswire PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif., Jan. 4, 2024 - Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on...

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program PR Newswire PLYMOUTH MEETING, Pa., Jan. 3, 2024 Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review process Accelerating commercialization efforts to be prepared to launch INO-3107 in 2025 PLYMOUTH MEETING, Pa. , Jan. 3, 2024 /PRNewswire/ -- INOVIO...

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights PR Newswire PLYMOUTH MEETING, Pa., Nov. 9, 2023 Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Received FDA feedback that data from completed Phase 1/2 trial could be used to submit a Biological License Application (BLA) under Accelerated...

INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Nov. 1, 2023 PLYMOUTH MEETING, Pa. , Nov. 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation...

INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 PR Newswire PLYMOUTH MEETING, Pa., Oct. 26, 2023 PLYMOUTH MEETING, Pa. , Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023 ....

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program PR Newswire PLYMOUTH MEETING, Pa., Oct. 10, 2023 Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus...

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire PLYMOUTH MEETING, Pa., Sept. 7, 2023 • Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First Breakthrough Therapy designation for an INOVIO DNA medicine candidate PLYMOUTH MEETING, Pa. , Sept. 7, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused...

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire PLYMOUTH MEETING, Pa., Aug. 29, 2023 PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO will present at the H.C. Wainwright 25th Annual Global...

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update PR Newswire PLYMOUTH MEETING, Pa., Aug. 9, 2023 Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the...

INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Aug. 4, 2023 PLYMOUTH MEETING, Pa. , Aug. 4, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan"). The...

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023 PR Newswire PLYMOUTH MEETING, Pa., July 26, 2023 PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023 ....

INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., June 1, 2023 PLYMOUTH MEETING, Pa. , June 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The...